Guillain-Barré Syndrome Following the Administration of Tarlatamab in Extensive-stage Small Cell Lung Cancer: A Case Report with Pathological Confirmation.
We report a rare case of Guillain-Barré syndrome (GBS) following treatment with tarlatamab, a bispecific T-cell engager targeting DLL3 and CD3, in a patient with extensive-stage small cell lung cancer (SCLC). After the initial dose, the patient developed grade 2 cytokine release syndrome, followed by progressive weakne...